New data show that FIRMAGON® (degarelix) is non-inferior to the combination of goserelin plus bicalutamide at reducing prostate volume in patients with advanced hormone-dependent prostate cancer while offering better relief from lower urinary tract symptoms
inTwo new studies presented at the 27th Annual European Association of Urology (EAU) Congress reported that…